mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancerAmaia Zabala‐Letona, Javier Muñoz, Arkaitz Carracedo et al.|Nature|2017Cited by 219
A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.Serena Di Cosimo, José Baselga, Yuqin Song et al.|Journal of Clinical Oncology|2010Cited by 67
Erratum: Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancerAmaia Zabala‐Letona, Javier Muñoz, Amaia Arruabarrena-Aristorena et al.|Nature|2018Cited by 5